Subscribe To

Price Alert Latest News Economic Calendar News

HLVX / HilleVax to Participate in November Investor Conferences

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events. Read More

Demo Live Account See Partner Details

Content Topics

Hillevax

Participate

November

Investor

Conferences

Stock

HLVX

Posted: Nov 10 2022, 18:30

Author Name: GlobeNewsWire

HLVX News

By GlobeNewsWire
November 1, 2023

HilleVax to Present at Upcoming Investor Conferences

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerci

By GlobeNewsWire
September 26, 2023

HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerc

By Seeking Alpha
August 30, 2023

HilleVax: Takeda's Norovirus Vaccine Spinout

HilleVax is developing a virus-like particle vaccine candidate, HIL-214, for norovirus-induced acute gastroenteritis. Norovirus is highly contagious a

By Zacks Investment Research
June 7, 2023

Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 56.8% in HilleVax, Inc. (HLVX). While the effectiveness of th

By Zacks Investment Research
December 14, 2022

After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement a

By Zacks Investment Research
December 13, 2022

Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with

By Zacks Investment Research
November 18, 2022

Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.

By GlobeNewsWire
November 10, 2022

HilleVax to Participate in November Investor Conferences

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerci

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.